Microbix Biosystems Inc.

Equities

MBX

CA59501P1045

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 20:19:21 08/05/2024 BST			5-day change	1st Jan Change
0.33 ^CAD	-4.35%		-2.94%	-15.38%

04-25	Microbix to Present New Lab Accreditation Program at European Congress on Clinical Microbiology	MT
04-25	Microbix Collaborator Introduces New Lab Accreditation Program	CI

Tranche Update on Microbix Biosystems Inc.'s Equity Buyback Plan announced on December 6, 2023.

February 14, 2024 at 12:11 pm

From December 6, 2023 to December 31, 2023, the company has repurchased 141,360 shares, representing 0.1% for CAD 0.05 million. With this, the company has completed the repurchase of 141,360 shares, representing 0.1% for CAD 0.05 million under the buyback announced on December 6, 2023.

Latest news about Microbix Biosystems Inc.

Microbix to Present New Lab Accreditation Program at European Congress on Clinical Microbiology	04-25	MT
Microbix Collaborator Introduces New Lab Accreditation Program	04-25	CI
Transcript : Microbix Biosystems Inc. - Shareholder/Analyst Call	03-27
Microbix Says Clot-Buster Drug Project Advancing	03-14	MT
Microbix Brief: Says Clot-Buster Drug Project Advancing	03-14	MT
Microbix?S Clot-Buster Drug Project Advances	03-14	CI
Microbix Unveiling Test Controls for Head and Neck Cancer	03-11	MT
Microbix Brief: Unveiling Test Controls for Head and Neck Cancer	03-11	MT
Microbix Biosystems Inc. Unveils Test Controls for Head and Neck Cancer	03-11	CI
Microbix Higher After Reporting Record Results for Q1 Fiscal 2024	02-14	MT
Transcript : Microbix Biosystems Inc., Q1 2024 Earnings Call, Feb 14, 2024	02-14
Earnings Flash (MBX) MICROBIX BIOSYSTEMS Posts Q1 Revenue $8.4M	02-14	MT
Tranche Update on Microbix Biosystems Inc.'s Equity Buyback Plan announced on December 6, 2023.	02-14	CI
Microbix Biosystems Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
North American Morning Briefing :Stock Futures -2-	02-14	DJ
Microbix Unveiling Test Control for Gastric Ulcer Disease Pathogen	02-06	MT
Microbix Brief: Unveiling Test Control for Gastric Ulcer Disease Pathogen	02-06	MT
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen	02-06	CI
Microbix Systems Provides Update on QAP Sales	01-03	MT
Microbix Brief: Says Achieved Further QAPs Sales Record; Includes Over C$1 Million in One Shipment to a Leading Lab Accreditation Agency	01-03	MT
Transcript : Microbix Biosystems Inc., Q4 2023 Earnings Call, Jan 03, 2024	01-03
Microbix Reports Q4 Income of $2 Million	12-21	MT
Microbix Brief: Q4 Net Comprehensive Income per share 0.014 Vs (0.009) a Year Ago	12-21	MT
Microbix Brief: Q4 revenue was $4,264,229, relatively flat from Q4 2022 revenues	12-21	MT
Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024	12-21	CI

Chart Microbix Biosystems Inc.

Duration

Period

More charts

Company Profile

Microbix Biosystems Inc. is a Canada-based life science company, which develops and commercializes biological and technological solutions for human health and wellbeing. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, mainly antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. It operates through two segments: the development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and the development and commercialization of products or technologies such as Kinlytic. Its Kinlyti urokinase is a biologic thrombolytic drug used to treat blood clots.

Sector

Biotechnology & Medical Research

Calendar

08/05/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.33 CAD

Average target price

0.8 CAD

Spread / Average Target

+142.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MICROBIX BIOSYSTEMS INC.	-15.38%	33.05M
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research